Policy Revised: June 1st, 2021
Spark Biomedical, Inc. (“Spark”) conducts research and development activities which are often supported by small business grants from federal agencies. The purpose of this Financial Conflict of Interest (FCOI) policy is to document and define our standards and procedures for identifying and managing financial conflicts of interests to safeguard the integrity of research conducted by Spark and our subawardees and contractors.
This policy has been developed to comply with the following regulations:
This policy will be publicly available on the Spark website at: https://www.sparkbiomedical.com/fcoipolicy
This policy applies to investigators participating in, or planning to participate in, the design, conduct, or reporting of research and research proposals. This policy does not apply to research and development conducted under Phase I Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) awards.
For federally-supported research projects involving subawardees or contractors (collectively “subrecipients”), the subrecipient institutions are required to provide written assurance that a FCOI policy is in effect that is compliant with all applicable federal regulations, or that the subrecipient will conform to and abide by Spark FCOI policy and procedures.
Spark and all participating subawardees and contractors are required to complete training related to Financial Conflict of Interest (FOCI). If any conflicts of interest are found or known, they are required to be disclosed. FCOI training m.ust be updated no less than every three years or as designated based on specific grant requirements or project role
Spark FCOI training is conducted through the NIH Financial Conflict of Interest Tutorial available through the National Institutes of Health (NIH), which was designed to provide education training on what constitutes financial conflict of interest. Upon completion of the training tutorial, a certificate completion is generated, which must be turned in to the Chief Financial Officer (CFO).
SIGNIFICANT FINANCIAL INTEREST (SFI)
Significant Financial Interest is defined by federal regulations as:
A financial interest consisting of one or more of the following interests of the investigator (and those of the investigator’s spouse and dependent children) that reasonable appears to be related to the Investigators institutional responsibilities:
FINANCIAL CONFLICT OF INTEREST (FCOI)
A Financial Conflict of Interest exists when Spark reasonably determines that a SFI (as defined above) could directly and significantly affect the design, conduct, or reporting of federally funded research.
It is the responsibility of the Principal Investigator (PI) of a research project to identify all participating Investigators who have a SFI which would require disclosure under this policy. It is also the responsibility of the PI to conduct an annual review to identify any new SFI or to update existing disclosures.
All Investigators with an identified SFI must prepare and submit a SFI Disclosure Form (“Disclosure”) to Spark’ designated FCOI official(s), who will review all disclosures and evaluate whether an applicable FCOI exists. If no FCOI is determined, the SFI Disclosure Form will be kept on file by the CFO. If a FCOI is identified prior to the start of the research project, an FCOI report will be submitted to the awarding agency prior to expending any funds. If any FCOI is subsequently identified during the course of the research project, Spark will submit an FCOI report to the awarding agency within 60 days of receiving the disclosure. If it is found that an investigator conducted or participated in research with an undisclosed FCOI, Spark is required to disclose the FCOI in all public presentations of the results of the research.
MANAGEMENT OF IDENTIFIED FCOI
When Spark’ designated FCOI official(s) determines that a FCOI exists, steps will be taken to reduce or eliminate the FCOI to ensure that the design, conduct, and reporting of research will be free from bias to the maximum extent possible. A management plan may be required to establish terms, conditions, and restrictions to ensure compliance with this policy. A management plan may require one or more of the following actions:
All management plans are required to be signed by the Investigator and the CFO, and compliance to the management plan will be monitored by the CFO.
ENFORCEMENT OF FCOI POLICY
If an Investigator fails to comply with Spark’ FCOI policy, the CFO will make recommendations to the Board of Directors regarding the imposition of sanctions, disciplinary proceedings, or termination of the Investigator. In addition, Spark will follow federal regulations regarding the notification of the awarding agency if an Investigator has been found to have violated this policy. The federal agency may take subsequent action as appropriate, including suspension of funding for the Investigator until FCOI compliance is resolved.
Investigator SFI disclosure, records of FCOI determinations, and FCOI management plans will be retained by the CFO for three (3) years from the date the final expenditures report is submitted to the awarding agency.
POINT OF CONTACT
If you have a conflict of interest to report or have a question regarding the FCOI policy, contact Spark’ FCOI Official:
Alejandro Covalin. Ph.D. (AOR)
Chief Technology Officer
Spark Biomedical, Inc.
Not ready to schedule a consultation? That's OK. Just fill out the information below and we'll send you a copy of our brochure and be sure you're the first to know about any upcoming Spark Biomedical news or events.
Out of respect for the patients seeking help and the physicians researching life-saving treatment options, we ask that vendors not use this form to contact Spark Biomedical. Vendor solicitations in this format serve only to distract us from our mission. We appreciate your understanding and cooperation.